Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 3 Skin Neoplasms 2 Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Skin Diseases 1 Rectal Neoplasms 1 Rectal Diseases 1 Neoplasm Metastasis 1 Intestinal Neoplasms 1 Intestinal Diseases 1 Gastrointestinal Neoplasms 1 Gastrointestinal Diseases 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Colonic Diseases 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 13 Cisplatin 11 durvalumab 7 Oxaliplatin 5 Capecitabine 5 Fluorouracil 4 S 1 (combination) 3 Leucovorin 3 Irinotecan 3 zanidatamab 2 gemcitabine-oxaliplatin regimen 2 Trastuzumab 2 trastuzumab deruxtecan 1 pembrolizumab 1 niraparib 1 neratinib 1 ivosidenib 1 futibatinib 1 envafolimab 1 encorafenib 1 binimetinib 1 becatecarin 1 Tegafur 1 Pancreaticojejunostomy 1 NUC-1031 1 Folfox protocol 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Biliary Tract Neoplasms × encorafenib × Clear all

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡